LIBRETTO-432: A phase 3 randomized double-blind placebo-controlled trial of adjuvant selpercatinib after definitive locoregional treatment in NSCLC fusion-positive stage IB-IIIA RET participants
Biomarker: RET
LIBRETTO-432: A double-blind randomized placebo-controlled phase 3 study of adjuvant selpercatinib after definitive locoregional treatment in participants with stage IB-IIIA RET positive NSCLC fusion
LIBRETTO-432: A double-blind, randomized, placebo-controlled phase 3 study of adjunctive selpercatinib after definitive locoregional treatment in participants with stage IB-IIIA RET positive for NSCLC fusion
